Long-Term (>8 Years) Evaluation of Progression in Patients with Low-Pressure Glaucoma

Abstract

Purpose

To describe the long-term clinical course of patients with low-pressure glaucoma (LPG) and to assess the risk factors for disease progression.

Methods

The Wills Eye Glaucoma Research Center retrospectively reviewed the charts of LPG patients with documented follow-up of >8 years between 2000 and 2013. Medical records were evaluated for systemic diseases, family history of glaucoma, best-corrected visual acuity, refractive error, treatments, central corneal thickness (CCT), intraocular pressure (IOP), IOP change after pupil dilation, optic disc evaluation, visual field (VF) mean deviation (MD), VF grading, and time to progression. Progression was determined when both disc and VF appeared to have worsened.

Results

From 850 charts classified as LPG between 2000 and 2013, 49 eyes of 49 patients were included in our analysis. The mean (± SD) follow-up time was 9.3 (± 1.9) years. Glaucoma progressed in 25 eyes and remained stable in 24 eyes over the follow-up period. Eyes with progression had higher peak IOP (p = 0.043). There was a trend towards progression in patients with thinner CCT (p = 0.085) and disc hemorrhage (p = 0.098). Estimated annual change in MD was −0.57 dB in the progressing group and −0.10 dB in the stable group (p<0.0001).

Conclusions

Nearly half of the patients with LPG showed glaucoma progression despite treatment after >8 years. High peak IOP was a significant risk factor for progression. Identifying patients at risk may warrant closer follow-up and more aggressive treatment in order to preserve visual function in patients with LPG.

Keywords

Glaucoma progression Long-term evaluation Low-pressure glaucoma Normal-tension glaucoma

Get full access to this article

View all access options for this article.

References

Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998; 126: 487–97.

Anderson

D.R.

Drance

S.M.

Schulzer

; Collaborative NormalTension Glaucoma Study Group. Natural history of normaltension glaucoma. Ophthalmology. 2001; 108: 247–53.

Shields

M.B.

. Normal-tension glaucoma: is it different from primary open-angle glaucoma? Curr Opin Ophthalmol. 2008; 19: 85–8.

Eid

T.M.

Spaeth

G.L.

Bitterman

Steinmann

W.C.

. Rate and amount of visual loss in 102 patients with open-angle glaucoma followed up for at least 15 years. Ophthalmology. 2003; 110: 900–7.

Kim

D.M.

Park

K.H.

Kim

T.W.

Jeoung

J.W.

Kim

S.H.

. Intraocular pressure reduction with topical medications and progression of normal-tension glaucoma: a 12-year mean follow-up study. Acta Ophthalmol. 2013; 91: e270–5.

Komori

Ishida

Yamamoto

. Results of long-term monitoring of normal-tension glaucoma patients receiving medical therapy: results of an 18-year follow-up. Graefes Arch Clin Exp Ophthalmol. 2014; 252: 1963–70.

Sakata

Aihara

Murata

Intraocular pressure change over a habitual 24-hour period after changing posture or drinking water and related factors in normal tension glaucoma. Invest Ophthalmol Vis Sci. 2013; 54: 5313–20.

Leske

M.C.

Heijl

Hyman

Bengtsson

Dong

Yang

; EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114: 1965–72.

Kass

M.A.

Heuer

D.K.

Higginbotham

E.J.

The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120: 701–13, discussion 829–30.

10.

Gordon

M.O.

Beiser

J.A.

Brandt

J.D.

The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120: 714–20, discussion 829–30.

11.

Musch

D.C.

Gillespie

B.W.

Lichter

P.R.

Niziol

L.M.

Janz

N.K.

; CIGTS Study Investigators. Visual field progression in the Collaborative Initial Glaucoma Treatment Study: the impact of treatment and other baseline factors. Ophthalmology. 2009; 116: 200–7.

12.

De Moraes

C.G.

Liebmann

J.M.

Greenfield

D.S.

Gardiner

S.K.

Ritch

Krupin

; Low-pressure Glaucoma Treatment Study Group. Risk factors for visual field progression in the low-pressure glaucoma treatment study. Am J Ophthalmol. 2012; 154: 702–11.

13.

Drance

Anderson

D.R.

Schulzer

; Collaborative NormalTension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol. 2001; 131: 699–708.

14.

Kaiser

H.J.

Flammer

. Systemic hypotension: a risk factor for glaucomatous damage? Ophthalmologica. 1991; 203: 105–8.

15.

Hayreh

S.S.

Zimmerman

M.B.

Podhajsky

Alward

W.L.

. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994; 117: 603–24.

16.

Graham

S.L.

Drance

S.M.

Wijsman

Douglas

G.R.

Mikelberg

F.S.

. Ambulatory blood pressure monitoring in glaucoma: the nocturnal dip. Ophthalmology. 1995; 102: 61–9.

17.

Phelps

C.D.

Corbett

J.J.

. Migraine and low-tension glaucoma: a case-control study. Invest Ophthalmol Vis Sci. 1985; 26: 1105–8.

18.

Anderson

D.R.

Drance

S.M.

Schulzer

; Collaborative NormalTension Glaucoma Study Group. Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. Am J Ophthalmol. 2003; 136: 820–9.

19.

Shields

M.B.

. Normal-tension glaucoma: is it different from primary open-angle glaucoma? Curr Opin Ophthalmol. 2008; 19: 85–8.

20.

Ramdas

W.D.

Wolfs

R.C.

Hofman

de Jong

P.T.

Vingerling

J.R.

Jansonius

N.M.

. Ocular perfusion pressure and the incidence of glaucoma: real effect or artifact? The Rotterdam Study. Invest Ophthalmol Vis Sci. 2011; 52: 6875–81.

21.

Ishida

Yamamoto

Sugiyama

Kitazawa

. Disk hemorrhage is a significantly negative prognostic factor in normal-tension glaucoma. Am J Ophthalmol. 2000; 129: 707–14.

22.

Medeiros

F.A.

Sample

P.A.

Zangwill

L.M.

Bowd

Aihara

Weinreb

R.N.

. Corneal thickness as a risk factor for visual field loss in patients with preperimetric glaucomatous optic neuropathy. Am J Ophthalmol. 2003; 136: 805–13.

23.

Prata

T.S.

De Moraes

C.G.V.

Teng

C.C.

Tello

Ritch

Liebmann

J.M.

. Factors affecting rates of visual field progression in glaucoma patients with optic disc hemorrhage. Ophthalmology. 2010; 117: 24–9.

24.

Forchheimer

de Moraes

C.G.

Teng

C.C.

Baseline mean deviation and rates of visual field change in treated glaucoma patients. Eye. 2011; 25: 626–32.